In:
Journal of Cachexia, Sarcopenia and Muscle, Wiley, Vol. 14, No. 6 ( 2023-12), p. 2747-2756
Abstract:
We examined the incidence and predictors of clinical outcomes in metabolic dysfunction‐associated fatty liver disease (MAFLD), focusing on anthropometric parameters. Methods Adult patients with MAFLD were identified in nationwide databases and a hospital cohort. Primary endpoints were atherosclerotic cardiovascular disease (ASCVD) and advanced fibrosis. Logistic and Cox regression analyses were used to analyse the association between anthropometric parameters and endpoints. Results In total, 4407 of 15 256 (28.9%) and 6274 of 25 784 subjects (24.3%) had MAFLD in the nationwide database; of these, 403 (9.2%) and 437 (7.0%) subjects were of lean/normal weight, respectively. Compared to the overweight/obese group, the lean/normal weight group had a significantly lower muscle mass (15.0 vs. 18.9 kg) and handgrip strength (31.9 vs. 35.1 kg) and had a higher ASCVD risk (9.0% vs. 6.3% and 15.9% vs. 8.5%; P s 〈 0.001). Sarcopenia (odds ratio [OR], 6.66; 95% confidence interval [CI] , 1.79–24.80) and handgrip strength (OR, 0.92; 95% CI, 0.86–0.97; P s = 0.005) were associated with the ASCVD risk in the lean/normal weight group. In a hospital cohort ( n = 1363), the ASCVD risk was significantly higher in the lean/normal weight group than in the overweight/obese group (median follow‐up, 39.1 months). Muscle mass was inversely correlated with the ASCVD risk (hazard ratio [HR], 0.72; 95% CI, 0.56–0.94), while visceral adiposity was associated with advanced fibrosis (HR, 1.36; 95% CI, 1.10–1.69; P s 〈 0.05). Conclusions Muscle mass/strength was significantly associated with the ASCVD risk in patients with MAFLD. Visceral adiposity was an independent predictor of advanced fibrosis.
Type of Medium:
Online Resource
ISSN:
2190-5991
,
2190-6009
Language:
English
Publisher:
Wiley
Publication Date:
2023
detail.hit.zdb_id:
2586864-0
Permalink